Artivion, Inc.
Artivion, Inc. (AORT) Stock Competitors & Peer Comparison
See (AORT) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
---|---|---|---|---|---|---|
AORT | $30.91 | -2.09% | 1.3B | -60.71 | -$0.51 | N/A |
ABT | $126.19 | -1.84% | 219.6B | 15.81 | $7.98 | +1.80% |
BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
BSX | $104.92 | -1.72% | 155.2B | 62.44 | $1.68 | N/A |
SYK | $392.73 | -1.92% | 150.7B | 53.20 | $7.41 | +0.83% |
MDT | $90.24 | -1.53% | 115.6B | 25.00 | $3.61 | +3.10% |
EW | $79.31 | -2.28% | 46.5B | 33.18 | $2.39 | N/A |
DXCM | $80.77 | -9.31% | 31.7B | 56.87 | $1.42 | N/A |
PHG | $26.20 | -2.28% | 24.9B | 145.50 | $0.18 | +3.36% |
STE | $226.49 | -1.21% | 22.3B | 36.71 | $6.17 | +1.00% |
Stock Comparison
AORT vs ABT Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, ABT has a market cap of 219.6B. Regarding current trading prices, AORT is priced at $30.91, while ABT trades at $126.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas ABT's P/E ratio is 15.81. In terms of profitability, AORT's ROE is -0.07%, compared to ABT's ROE of +0.32%. Regarding short-term risk, AORT is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check ABT's competition here
AORT vs BSX-PA Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, AORT is priced at $30.91, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, AORT's ROE is -0.07%, compared to BSX-PA's ROE of +0.12%. Regarding short-term risk, AORT is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check BSX-PA's competition here
AORT vs BSX Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, BSX has a market cap of 155.2B. Regarding current trading prices, AORT is priced at $30.91, while BSX trades at $104.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas BSX's P/E ratio is 62.44. In terms of profitability, AORT's ROE is -0.07%, compared to BSX's ROE of +0.12%. Regarding short-term risk, AORT is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check BSX's competition here
AORT vs SYK Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, SYK has a market cap of 150.7B. Regarding current trading prices, AORT is priced at $30.91, while SYK trades at $392.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas SYK's P/E ratio is 53.20. In terms of profitability, AORT's ROE is -0.07%, compared to SYK's ROE of +0.11%. Regarding short-term risk, AORT is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check SYK's competition here
AORT vs MDT Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, MDT has a market cap of 115.6B. Regarding current trading prices, AORT is priced at $30.91, while MDT trades at $90.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas MDT's P/E ratio is 25.00. In terms of profitability, AORT's ROE is -0.07%, compared to MDT's ROE of +0.10%. Regarding short-term risk, AORT is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check MDT's competition here
AORT vs EW Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, EW has a market cap of 46.5B. Regarding current trading prices, AORT is priced at $30.91, while EW trades at $79.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas EW's P/E ratio is 33.18. In terms of profitability, AORT's ROE is -0.07%, compared to EW's ROE of +0.45%. Regarding short-term risk, AORT is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check EW's competition here
AORT vs DXCM Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, DXCM has a market cap of 31.7B. Regarding current trading prices, AORT is priced at $30.91, while DXCM trades at $80.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas DXCM's P/E ratio is 56.87. In terms of profitability, AORT's ROE is -0.07%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, AORT is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check DXCM's competition here
AORT vs PHG Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, PHG has a market cap of 24.9B. Regarding current trading prices, AORT is priced at $30.91, while PHG trades at $26.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas PHG's P/E ratio is 145.50. In terms of profitability, AORT's ROE is -0.07%, compared to PHG's ROE of +0.03%. Regarding short-term risk, AORT is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check PHG's competition here
AORT vs STE Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, STE has a market cap of 22.3B. Regarding current trading prices, AORT is priced at $30.91, while STE trades at $226.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas STE's P/E ratio is 36.71. In terms of profitability, AORT's ROE is -0.07%, compared to STE's ROE of +0.09%. Regarding short-term risk, AORT is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check STE's competition here
AORT vs PODD Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, PODD has a market cap of 20.3B. Regarding current trading prices, AORT is priced at $30.91, while PODD trades at $288.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas PODD's P/E ratio is 52.06. In terms of profitability, AORT's ROE is -0.07%, compared to PODD's ROE of +0.35%. Regarding short-term risk, AORT is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check PODD's competition here
AORT vs ZBH Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, ZBH has a market cap of 18.1B. Regarding current trading prices, AORT is priced at $30.91, while ZBH trades at $91.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas ZBH's P/E ratio is 20.37. In terms of profitability, AORT's ROE is -0.07%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, AORT is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check ZBH's competition here
AORT vs ABMD Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, AORT is priced at $30.91, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas ABMD's P/E ratio is 65.36. In terms of profitability, AORT's ROE is -0.07%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, AORT is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check ABMD's competition here
AORT vs SNN Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, SNN has a market cap of 13.4B. Regarding current trading prices, AORT is priced at $30.91, while SNN trades at $30.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas SNN's P/E ratio is 32.52. In terms of profitability, AORT's ROE is -0.07%, compared to SNN's ROE of +0.08%. Regarding short-term risk, AORT is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check SNN's competition here
AORT vs SWAV Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, AORT is priced at $30.91, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas SWAV's P/E ratio is 78.76. In terms of profitability, AORT's ROE is -0.07%, compared to SWAV's ROE of +0.14%. Regarding short-term risk, AORT is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check SWAV's competition here
AORT vs PEN Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, PEN has a market cap of 9.8B. Regarding current trading prices, AORT is priced at $30.91, while PEN trades at $252.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas PEN's P/E ratio is 66.62. In terms of profitability, AORT's ROE is -0.07%, compared to PEN's ROE of +0.12%. Regarding short-term risk, AORT is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check PEN's competition here
AORT vs ALGN Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, ALGN has a market cap of 9.4B. Regarding current trading prices, AORT is priced at $30.91, while ALGN trades at $129.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas ALGN's P/E ratio is 21.79. In terms of profitability, AORT's ROE is -0.07%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, AORT is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check ALGN's competition here
AORT vs GMED Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, GMED has a market cap of 7.1B. Regarding current trading prices, AORT is priced at $30.91, while GMED trades at $52.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas GMED's P/E ratio is 39.27. In terms of profitability, AORT's ROE is -0.07%, compared to GMED's ROE of +0.05%. Regarding short-term risk, AORT is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check GMED's competition here
AORT vs BIO-B Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, BIO-B has a market cap of 6.8B. Regarding current trading prices, AORT is priced at $30.91, while BIO-B trades at $247.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas BIO-B's P/E ratio is -3.23. In terms of profitability, AORT's ROE is -0.07%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, AORT is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check BIO-B's competition here
AORT vs BIO Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, BIO has a market cap of 6.6B. Regarding current trading prices, AORT is priced at $30.91, while BIO trades at $241.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas BIO's P/E ratio is -3.16. In terms of profitability, AORT's ROE is -0.07%, compared to BIO's ROE of -0.32%. Regarding short-term risk, AORT is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check BIO's competition here
AORT vs BRKR Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, BRKR has a market cap of 5.8B. Regarding current trading prices, AORT is priced at $30.91, while BRKR trades at $38.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas BRKR's P/E ratio is 73.90. In terms of profitability, AORT's ROE is -0.07%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, AORT is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check BRKR's competition here
AORT vs GKOS Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, GKOS has a market cap of 4.9B. Regarding current trading prices, AORT is priced at $30.91, while GKOS trades at $86.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas GKOS's P/E ratio is -37.93. In terms of profitability, AORT's ROE is -0.07%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, AORT is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check GKOS's competition here
AORT vs NARI Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, AORT is priced at $30.91, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas NARI's P/E ratio is -59.24. In terms of profitability, AORT's ROE is -0.07%, compared to NARI's ROE of -0.18%. Regarding short-term risk, AORT is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check NARI's competition here
AORT vs IRTC Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, IRTC has a market cap of 4.5B. Regarding current trading prices, AORT is priced at $30.91, while IRTC trades at $140.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas IRTC's P/E ratio is -44.79. In terms of profitability, AORT's ROE is -0.07%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, AORT is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check IRTC's competition here
AORT vs TMDX Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, TMDX has a market cap of 4B. Regarding current trading prices, AORT is priced at $30.91, while TMDX trades at $118.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas TMDX's P/E ratio is 83.78. In terms of profitability, AORT's ROE is -0.07%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, AORT is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check TMDX's competition here
AORT vs ITGR Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, ITGR has a market cap of 3.8B. Regarding current trading prices, AORT is priced at $30.91, while ITGR trades at $108.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas ITGR's P/E ratio is 46.40. In terms of profitability, AORT's ROE is -0.07%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, AORT is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check ITGR's competition here
AORT vs INSP Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, INSP has a market cap of 3.7B. Regarding current trading prices, AORT is priced at $30.91, while INSP trades at $124.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas INSP's P/E ratio is 56.90. In terms of profitability, AORT's ROE is -0.07%, compared to INSP's ROE of +0.10%. Regarding short-term risk, AORT is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check INSP's competition here
AORT vs AXNX Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, AORT is priced at $30.91, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas AXNX's P/E ratio is -709.80. In terms of profitability, AORT's ROE is -0.07%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, AORT is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check AXNX's competition here
AORT vs PRCT Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, PRCT has a market cap of 2.7B. Regarding current trading prices, AORT is priced at $30.91, while PRCT trades at $48.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas PRCT's P/E ratio is -28.70. In terms of profitability, AORT's ROE is -0.07%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, AORT is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check PRCT's competition here
AORT vs LIVN Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, LIVN has a market cap of 2.3B. Regarding current trading prices, AORT is priced at $30.91, while LIVN trades at $42.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas LIVN's P/E ratio is -10.37. In terms of profitability, AORT's ROE is -0.07%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, AORT is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check LIVN's competition here
AORT vs NUVA Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, AORT is priced at $30.91, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas NUVA's P/E ratio is 75.00. In terms of profitability, AORT's ROE is -0.07%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, AORT is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check NUVA's competition here
AORT vs UFPT Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, AORT is priced at $30.91, while UFPT trades at $226.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas UFPT's P/E ratio is 27.81. In terms of profitability, AORT's ROE is -0.07%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, AORT is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check UFPT's competition here
AORT vs CNMD Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, CNMD has a market cap of 1.6B. Regarding current trading prices, AORT is priced at $30.91, while CNMD trades at $51.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas CNMD's P/E ratio is 13.42. In terms of profitability, AORT's ROE is -0.07%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, AORT is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check CNMD's competition here
AORT vs ATEC Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, AORT is priced at $30.91, while ATEC trades at $10.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas ATEC's P/E ratio is -9.29. In terms of profitability, AORT's ROE is -0.07%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, AORT is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check ATEC's competition here
AORT vs HSKA Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, AORT is priced at $30.91, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas HSKA's P/E ratio is -62.49. In terms of profitability, AORT's ROE is -0.07%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, AORT is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check HSKA's competition here
AORT vs SSII Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, SSII has a market cap of 1.3B. Regarding current trading prices, AORT is priced at $30.91, while SSII trades at $6.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas SSII's P/E ratio is -83.75. In terms of profitability, AORT's ROE is -0.07%, compared to SSII's ROE of -1.05%. Regarding short-term risk, AORT is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check SSII's competition here
AORT vs ESTA Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, ESTA has a market cap of 1.2B. Regarding current trading prices, AORT is priced at $30.91, while ESTA trades at $41.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas ESTA's P/E ratio is -13.45. In terms of profitability, AORT's ROE is -0.07%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, AORT is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check ESTA's competition here
AORT vs AHCO Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, AHCO has a market cap of 1.2B. Regarding current trading prices, AORT is priced at $30.91, while AHCO trades at $8.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas AHCO's P/E ratio is 15.47. In terms of profitability, AORT's ROE is -0.07%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, AORT is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check AHCO's competition here
AORT vs SILK Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, AORT is priced at $30.91, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas SILK's P/E ratio is -18.96. In terms of profitability, AORT's ROE is -0.07%, compared to SILK's ROE of -0.29%. Regarding short-term risk, AORT is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check SILK's competition here
AORT vs FNA Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, AORT is priced at $30.91, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas FNA's P/E ratio is -19.83. In terms of profitability, AORT's ROE is -0.07%, compared to FNA's ROE of -0.36%. Regarding short-term risk, AORT is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check FNA's competition here
AORT vs TNDM Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, TNDM has a market cap of 1B. Regarding current trading prices, AORT is priced at $30.91, while TNDM trades at $15.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas TNDM's P/E ratio is -5.58. In terms of profitability, AORT's ROE is -0.07%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, AORT is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check TNDM's competition here
AORT vs IART Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, IART has a market cap of 1B. Regarding current trading prices, AORT is priced at $30.91, while IART trades at $13.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas IART's P/E ratio is -34.58. In terms of profitability, AORT's ROE is -0.07%, compared to IART's ROE of -0.03%. Regarding short-term risk, AORT is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check IART's competition here
AORT vs INMD Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, INMD has a market cap of 950.2M. Regarding current trading prices, AORT is priced at $30.91, while INMD trades at $13.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas INMD's P/E ratio is 6.13. In terms of profitability, AORT's ROE is -0.07%, compared to INMD's ROE of +0.27%. Regarding short-term risk, AORT is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check INMD's competition here
AORT vs CSII Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, AORT is priced at $30.91, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas CSII's P/E ratio is -20.83. In terms of profitability, AORT's ROE is -0.07%, compared to CSII's ROE of -0.14%. Regarding short-term risk, AORT is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check CSII's competition here
AORT vs SMLR Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, SMLR has a market cap of 831.3M. Regarding current trading prices, AORT is priced at $30.91, while SMLR trades at $35.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas SMLR's P/E ratio is -15.00. In terms of profitability, AORT's ROE is -0.07%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, AORT is less volatile compared to SMLR. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check SMLR's competition here
AORT vs IRMD Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, IRMD has a market cap of 741.8M. Regarding current trading prices, AORT is priced at $30.91, while IRMD trades at $58.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas IRMD's P/E ratio is 37.64. In terms of profitability, AORT's ROE is -0.07%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, AORT is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check IRMD's competition here
AORT vs SIBN Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, SIBN has a market cap of 725.7M. Regarding current trading prices, AORT is priced at $30.91, while SIBN trades at $17.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas SIBN's P/E ratio is -27.03. In terms of profitability, AORT's ROE is -0.07%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, AORT is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check SIBN's competition here
AORT vs CRY Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, AORT is priced at $30.91, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas CRY's P/E ratio is 425.71. In terms of profitability, AORT's ROE is -0.07%, compared to CRY's ROE of -0.07%. Regarding short-term risk, AORT is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check CRY's competition here
AORT vs AXGN Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, AXGN has a market cap of 596.2M. Regarding current trading prices, AORT is priced at $30.91, while AXGN trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas AXGN's P/E ratio is -81.81. In terms of profitability, AORT's ROE is -0.07%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, AORT is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check AXGN's competition here
AORT vs APEN Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, AORT is priced at $30.91, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas APEN's P/E ratio is -9.43. In terms of profitability, AORT's ROE is -0.07%, compared to APEN's ROE of -0.85%. Regarding short-term risk, AORT is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check APEN's competition here
AORT vs ZIMV Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, ZIMV has a market cap of 529.9M. Regarding current trading prices, AORT is priced at $30.91, while ZIMV trades at $18.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas ZIMV's P/E ratio is -20.88. In terms of profitability, AORT's ROE is -0.07%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, AORT is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check ZIMV's competition here
AORT vs CBLL Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, CBLL has a market cap of 520.5M. Regarding current trading prices, AORT is priced at $30.91, while CBLL trades at $14.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas CBLL's P/E ratio is -11.61. In terms of profitability, AORT's ROE is -0.07%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, AORT is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check CBLL's competition here
AORT vs AVNS Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, AVNS has a market cap of 516.1M. Regarding current trading prices, AORT is priced at $30.91, while AVNS trades at $11.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas AVNS's P/E ratio is -1.35. In terms of profitability, AORT's ROE is -0.07%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, AORT is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check AVNS's competition here
AORT vs SRDX Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, SRDX has a market cap of 513.3M. Regarding current trading prices, AORT is priced at $30.91, while SRDX trades at $35.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas SRDX's P/E ratio is -25.64. In terms of profitability, AORT's ROE is -0.07%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, AORT is less volatile compared to SRDX. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check SRDX's competition here
AORT vs KIDS Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, KIDS has a market cap of 513.2M. Regarding current trading prices, AORT is priced at $30.91, while KIDS trades at $20.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas KIDS's P/E ratio is -11.77. In terms of profitability, AORT's ROE is -0.07%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, AORT is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check KIDS's competition here
AORT vs CTKB Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, CTKB has a market cap of 456M. Regarding current trading prices, AORT is priced at $30.91, while CTKB trades at $3.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas CTKB's P/E ratio is -40.00. In terms of profitability, AORT's ROE is -0.07%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, AORT is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check CTKB's competition here
AORT vs BFLY-WT Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, BFLY-WT has a market cap of 444M. Regarding current trading prices, AORT is priced at $30.91, while BFLY-WT trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, AORT's ROE is -0.07%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, AORT is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check BFLY-WT's competition here
AORT vs BVS Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, BVS has a market cap of 432.7M. Regarding current trading prices, AORT is priced at $30.91, while BVS trades at $6.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas BVS's P/E ratio is -13.58. In terms of profitability, AORT's ROE is -0.07%, compared to BVS's ROE of -0.21%. Regarding short-term risk, AORT is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check BVS's competition here
AORT vs OFIX Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, OFIX has a market cap of 432.6M. Regarding current trading prices, AORT is priced at $30.91, while OFIX trades at $11.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas OFIX's P/E ratio is -2.98. In terms of profitability, AORT's ROE is -0.07%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, AORT is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check OFIX's competition here
AORT vs BFLY Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, BFLY has a market cap of 420.4M. Regarding current trading prices, AORT is priced at $30.91, while BFLY trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas BFLY's P/E ratio is -5.68. In terms of profitability, AORT's ROE is -0.07%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, AORT is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check BFLY's competition here
AORT vs PACB Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, PACB has a market cap of 414.1M. Regarding current trading prices, AORT is priced at $30.91, while PACB trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas PACB's P/E ratio is -0.50. In terms of profitability, AORT's ROE is -0.07%, compared to PACB's ROE of -1.70%. Regarding short-term risk, AORT is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check PACB's competition here
AORT vs SENS Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, SENS has a market cap of 364.8M. Regarding current trading prices, AORT is priced at $30.91, while SENS trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas SENS's P/E ratio is -4.40. In terms of profitability, AORT's ROE is -0.07%, compared to SENS's ROE of -7.46%. Regarding short-term risk, AORT is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check SENS's competition here
AORT vs TMCI Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, TMCI has a market cap of 337.8M. Regarding current trading prices, AORT is priced at $30.91, while TMCI trades at $5.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas TMCI's P/E ratio is -6.32. In terms of profitability, AORT's ROE is -0.07%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, AORT is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check TMCI's competition here
AORT vs SNWV Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, SNWV has a market cap of 329.7M. Regarding current trading prices, AORT is priced at $30.91, while SNWV trades at $38.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas SNWV's P/E ratio is -6.17. In terms of profitability, AORT's ROE is -0.07%, compared to SNWV's ROE of +1.00%. Regarding short-term risk, AORT is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check SNWV's competition here
AORT vs RXST Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, RXST has a market cap of 316.2M. Regarding current trading prices, AORT is priced at $30.91, while RXST trades at $7.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas RXST's P/E ratio is -11.79. In terms of profitability, AORT's ROE is -0.07%, compared to RXST's ROE of -0.10%. Regarding short-term risk, AORT is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check RXST's competition here
AORT vs VREX Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, VREX has a market cap of 302.1M. Regarding current trading prices, AORT is priced at $30.91, while VREX trades at $7.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas VREX's P/E ratio is -7.07. In terms of profitability, AORT's ROE is -0.07%, compared to VREX's ROE of -0.08%. Regarding short-term risk, AORT is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check VREX's competition here
AORT vs NNOX Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, NNOX has a market cap of 300.3M. Regarding current trading prices, AORT is priced at $30.91, while NNOX trades at $4.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas NNOX's P/E ratio is -5.18. In terms of profitability, AORT's ROE is -0.07%, compared to NNOX's ROE of -0.31%. Regarding short-term risk, AORT is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check NNOX's competition here
AORT vs CLPT Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, CLPT has a market cap of 294M. Regarding current trading prices, AORT is priced at $30.91, while CLPT trades at $10.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas CLPT's P/E ratio is -13.68. In terms of profitability, AORT's ROE is -0.07%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, AORT is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check CLPT's competition here
AORT vs CATX Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, CATX has a market cap of 286.2M. Regarding current trading prices, AORT is priced at $30.91, while CATX trades at $3.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas CATX's P/E ratio is -3.13. In terms of profitability, AORT's ROE is -0.07%, compared to CATX's ROE of -0.27%. Regarding short-term risk, AORT is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check CATX's competition here
AORT vs OM Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, OM has a market cap of 284.6M. Regarding current trading prices, AORT is priced at $30.91, while OM trades at $16.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas OM's P/E ratio is -0.56. In terms of profitability, AORT's ROE is -0.07%, compared to OM's ROE of -1.45%. Regarding short-term risk, AORT is less volatile compared to OM. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check OM's competition here
AORT vs NPCE Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, NPCE has a market cap of 279.1M. Regarding current trading prices, AORT is priced at $30.91, while NPCE trades at $8.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas NPCE's P/E ratio is -10.38. In terms of profitability, AORT's ROE is -0.07%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, AORT is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check NPCE's competition here
AORT vs QTRX Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, QTRX has a market cap of 277.1M. Regarding current trading prices, AORT is priced at $30.91, while QTRX trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas QTRX's P/E ratio is -4.79. In terms of profitability, AORT's ROE is -0.07%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, AORT is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check QTRX's competition here
AORT vs CERS Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, CERS has a market cap of 244.7M. Regarding current trading prices, AORT is priced at $30.91, while CERS trades at $1.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas CERS's P/E ratio is -12.80. In terms of profitability, AORT's ROE is -0.07%, compared to CERS's ROE of -0.35%. Regarding short-term risk, AORT is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check CERS's competition here
AORT vs VMD Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, VMD has a market cap of 240.7M. Regarding current trading prices, AORT is priced at $30.91, while VMD trades at $6.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas VMD's P/E ratio is 20.30. In terms of profitability, AORT's ROE is -0.07%, compared to VMD's ROE of +0.10%. Regarding short-term risk, AORT is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check VMD's competition here
AORT vs MASS Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, MASS has a market cap of 234.9M. Regarding current trading prices, AORT is priced at $30.91, while MASS trades at $6.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas MASS's P/E ratio is -2.95. In terms of profitability, AORT's ROE is -0.07%, compared to MASS's ROE of -0.13%. Regarding short-term risk, AORT is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check MASS's competition here
AORT vs TCMD Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, TCMD has a market cap of 232M. Regarding current trading prices, AORT is priced at $30.91, while TCMD trades at $9.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas TCMD's P/E ratio is 15.12. In terms of profitability, AORT's ROE is -0.07%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, AORT is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check TCMD's competition here
AORT vs NVRO Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, AORT is priced at $30.91, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas NVRO's P/E ratio is -1.91. In terms of profitability, AORT's ROE is -0.07%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, AORT is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check NVRO's competition here
AORT vs BWAY Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, BWAY has a market cap of 220.7M. Regarding current trading prices, AORT is priced at $30.91, while BWAY trades at $11.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas BWAY's P/E ratio is 53.09. In terms of profitability, AORT's ROE is -0.07%, compared to BWAY's ROE of +0.07%. Regarding short-term risk, AORT is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check BWAY's competition here
AORT vs MXCT Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, MXCT has a market cap of 219M. Regarding current trading prices, AORT is priced at $30.91, while MXCT trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas MXCT's P/E ratio is -5.15. In terms of profitability, AORT's ROE is -0.07%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, AORT is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check MXCT's competition here
AORT vs EYES Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, AORT is priced at $30.91, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas EYES's P/E ratio is N/A. In terms of profitability, AORT's ROE is -0.07%, compared to EYES's ROE of -0.26%. Regarding short-term risk, AORT is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check EYES's competition here
AORT vs CVRX Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, CVRX has a market cap of 207.5M. Regarding current trading prices, AORT is priced at $30.91, while CVRX trades at $7.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas CVRX's P/E ratio is -3.72. In terms of profitability, AORT's ROE is -0.07%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, AORT is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check CVRX's competition here
AORT vs MGRM Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, MGRM has a market cap of 193.8M. Regarding current trading prices, AORT is priced at $30.91, while MGRM trades at $5.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas MGRM's P/E ratio is -10.72. In terms of profitability, AORT's ROE is -0.07%, compared to MGRM's ROE of -1.26%. Regarding short-term risk, AORT is less volatile compared to MGRM. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check MGRM's competition here
AORT vs SGHT Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, SGHT has a market cap of 172.2M. Regarding current trading prices, AORT is priced at $30.91, while SGHT trades at $3.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas SGHT's P/E ratio is -3.40. In terms of profitability, AORT's ROE is -0.07%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, AORT is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check SGHT's competition here
AORT vs INGN Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, INGN has a market cap of 169.7M. Regarding current trading prices, AORT is priced at $30.91, while INGN trades at $6.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas INGN's P/E ratio is -5.49. In terms of profitability, AORT's ROE is -0.07%, compared to INGN's ROE of -0.15%. Regarding short-term risk, AORT is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check INGN's competition here
AORT vs PROF Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, PROF has a market cap of 166.8M. Regarding current trading prices, AORT is priced at $30.91, while PROF trades at $5.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas PROF's P/E ratio is -4.59. In terms of profitability, AORT's ROE is -0.07%, compared to PROF's ROE of -0.70%. Regarding short-term risk, AORT is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check PROF's competition here
AORT vs TLSI Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, TLSI has a market cap of 160.6M. Regarding current trading prices, AORT is priced at $30.91, while TLSI trades at $4.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas TLSI's P/E ratio is -3.85. In terms of profitability, AORT's ROE is -0.07%, compared to TLSI's ROE of +1.04%. Regarding short-term risk, AORT is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check TLSI's competition here
AORT vs LNSR Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, LNSR has a market cap of 153.5M. Regarding current trading prices, AORT is priced at $30.91, while LNSR trades at $12.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas LNSR's P/E ratio is -2.65. In terms of profitability, AORT's ROE is -0.07%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, AORT is less volatile compared to LNSR. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check LNSR's competition here
AORT vs ELMD Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, ELMD has a market cap of 153M. Regarding current trading prices, AORT is priced at $30.91, while ELMD trades at $18.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas ELMD's P/E ratio is 23.09. In terms of profitability, AORT's ROE is -0.07%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, AORT is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check ELMD's competition here
AORT vs RPID Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, RPID has a market cap of 146M. Regarding current trading prices, AORT is priced at $30.91, while RPID trades at $3.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas RPID's P/E ratio is -3.23. In terms of profitability, AORT's ROE is -0.07%, compared to RPID's ROE of -0.56%. Regarding short-term risk, AORT is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check RPID's competition here
AORT vs BSGM Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, BSGM has a market cap of 144.7M. Regarding current trading prices, AORT is priced at $30.91, while BSGM trades at $4.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas BSGM's P/E ratio is -8.72. In terms of profitability, AORT's ROE is -0.07%, compared to BSGM's ROE of -35.30%. Regarding short-term risk, AORT is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check BSGM's competition here
AORT vs RCEL Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, RCEL has a market cap of 140.1M. Regarding current trading prices, AORT is priced at $30.91, while RCEL trades at $5.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas RCEL's P/E ratio is -2.42. In terms of profitability, AORT's ROE is -0.07%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, AORT is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check RCEL's competition here
AORT vs OWLT Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, OWLT has a market cap of 121.1M. Regarding current trading prices, AORT is priced at $30.91, while OWLT trades at $7.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas OWLT's P/E ratio is -4.55. In terms of profitability, AORT's ROE is -0.07%, compared to OWLT's ROE of +1.25%. Regarding short-term risk, AORT is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check OWLT's competition here
AORT vs AVR Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, AVR has a market cap of 119.7M. Regarding current trading prices, AORT is priced at $30.91, while AVR trades at $3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas AVR's P/E ratio is -0.93. In terms of profitability, AORT's ROE is -0.07%, compared to AVR's ROE of -2.92%. Regarding short-term risk, AORT is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check AVR's competition here
AORT vs ANIK Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, ANIK has a market cap of 118.4M. Regarding current trading prices, AORT is priced at $30.91, while ANIK trades at $8.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas ANIK's P/E ratio is -9.28. In terms of profitability, AORT's ROE is -0.07%, compared to ANIK's ROE of -0.35%. Regarding short-term risk, AORT is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check ANIK's competition here
AORT vs ICAD Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, AORT is priced at $30.91, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas ICAD's P/E ratio is -20.37. In terms of profitability, AORT's ROE is -0.07%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, AORT is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check ICAD's competition here
AORT vs LUCD Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, LUCD has a market cap of 105.9M. Regarding current trading prices, AORT is priced at $30.91, while LUCD trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas LUCD's P/E ratio is -0.84. In terms of profitability, AORT's ROE is -0.07%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, AORT is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check LUCD's competition here
AORT vs HJLI Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, AORT is priced at $30.91, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas HJLI's P/E ratio is N/A. In terms of profitability, AORT's ROE is -0.07%, compared to HJLI's ROE of -0.51%. Regarding short-term risk, AORT is less volatile compared to HJLI. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check HJLI's competition here
AORT vs FONR Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, FONR has a market cap of 96.8M. Regarding current trading prices, AORT is priced at $30.91, while FONR trades at $15.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas FONR's P/E ratio is 12.49. In terms of profitability, AORT's ROE is -0.07%, compared to FONR's ROE of +0.09%. Regarding short-term risk, AORT is more volatile compared to FONR. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check FONR's competition here
AORT vs QIPT Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, QIPT has a market cap of 96M. Regarding current trading prices, AORT is priced at $30.91, while QIPT trades at $2.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas QIPT's P/E ratio is -10.52. In terms of profitability, AORT's ROE is -0.07%, compared to QIPT's ROE of -0.08%. Regarding short-term risk, AORT is less volatile compared to QIPT. This indicates potentially lower risk in terms of short-term price fluctuations for AORT.Check QIPT's competition here
AORT vs ASXC Comparison August 2025
AORT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AORT stands at 1.3B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, AORT is priced at $30.91, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AORT currently has a P/E ratio of -60.71, whereas ASXC's P/E ratio is -1.12. In terms of profitability, AORT's ROE is -0.07%, compared to ASXC's ROE of -5.59%. Regarding short-term risk, AORT is more volatile compared to ASXC. This indicates potentially higher risk in terms of short-term price fluctuations for AORT.Check ASXC's competition here